CORPORATION (OTCMKTS:CCYPQ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Effective September15, 2017, Alexey Eliseev’s employment with RXi Pharmaceuticals Corporation (“RXi”) as Chief Business Officer of RXi ended. Dr.Eliseev’s termination will be treated as a termination without cause for purposes of the Employment Agreement, dated January6, 2017, between Dr.Eliseev and RXi, and Dr.Eliseev will receive severance benefits consistent with and subject to the conditions set forth in the Employment Agreement.
* * *
2